Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Renal denervation

13 evidence topics · 11 sources

Medicare coverage with evidence development: CMS national coverage decision

“The Centers for Medicare & Medicaid Services (CMS) will cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) (collectively, RDN) for uncontrolled hypertension under Coverage with Evidence Development (CED) according to the provisions in sections (B) and (C) below.” (opens the source at this quote in a new tab)

“(a) Diagnosis of uncontrolled hypertension (≥ 140 mm Hg systolic blood pressure and > 90 mm Hg diastolic blood pressure) despite active management by a clinician with primary responsibility for blood pressure management.” (opens the source at this quote in a new tab)

“(c) On lifestyle modifications and stable doses of maximally tolerated guideline-directed medical therapy (GDMT), with assessment of adherence to the prescribed regimen, for at least six weeks before referral for RDN.” (opens the source at this quote in a new tab)

“At a minimum, patients must be screened for primary aldosteronism, obstructive sleep apnea, and drug or alcohol induced hypertension before referral to RDN.” (opens the source at this quote in a new tab)

“The primary clinicians must coordinate management of the patient for a minimum of six months before referral for RDN, during which the patient had at least three encounters, with no more than two of the three encounters being virtual.” (opens the source at this quote in a new tab)